Log in to search using one of your social media accounts:

 

An IIT solution to 'expensive' biotechnology
Trastuzumab, a drug developed through bio-engineering, currently has a maximum retail price of Rs 52,000-58,602 for a 440 mg vial, depending on the brand, according to the National Pharmaceutical Pricing Authority. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2017 Category: Pharmaceuticals Source Type: news

No change in essential drugs' ceiling price calculation: Government
The Department of Pharmaceuticals also said that it is considering medicines that have become non-scheduled drugs to be sold without any freeze on prices for a further year. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2017 Category: Pharmaceuticals Source Type: news

Dr Reddy's Lab recalls Famotidine tablets from US market
As many as 5,69,376 bottles of Famotidine tablets, 10 mg belonging to multiple lots packaged in 30-count, are being recalled nationwide. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2017 Category: Pharmaceuticals Source Type: news

Now, government plans to cap margins of medical devices to bring down prices
Unlike price caps, fixing trade margins would restrict how much a product ’s price can be raised from the import or manufacturing cost. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2017 Category: Pharmaceuticals Source Type: news

Government plans to cap margins for medical devices to provide relief to industry
Unlike price caps, fixing trade margins would restrict how much a product ’s price can be raised from the import or manufacturing cost. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson blames price cuts in India for poor show in knee-implant business
The company's medical device business, which reported total Q3 revenue of $6.6 billion, saw the knee implant business decline to $343 million from $355 million. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2017 Category: Pharmaceuticals Source Type: news

Suven gets patent from Singapore for neurological molecule
Suven Life Sciences shares were trading 0.70 per cent up at Rs 223 on BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2017 Category: Pharmaceuticals Source Type: news

Popular antacid samples fail quality tests, company claims they were counterfeits
The Pantocid and Pantocid DSR tested by CDSCO were not manufactured by Sun Pharma, the official spokesperson for the Mumbai-based drug maker said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 17, 2017 Category: Pharmaceuticals Source Type: news

AstraZeneca Pharma India gets DCGI nod to market diabetes drug
The product is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes, AstraZeneca Pharma India said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 17, 2017 Category: Pharmaceuticals Source Type: news

Aurobindo Pharma gets USFDA nod for heartburn drug
Aurobindo Pharma said it "has received final approval from the US Food and Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 17, 2017 Category: Pharmaceuticals Source Type: news

After stents and knee implants, government now plans to put a price cap on non-essential drugs
Non-essential drugs are those that are outside the price-control regime. About 370 drugs are currently under price control. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 17, 2017 Category: Pharmaceuticals Source Type: news

Zydus Cadila gets USFDA nod to market Doxazosin tablets
The company has also received the tentative approval from the USFDA to market Lurasidone Hydrochloride Tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Zydus Cadila said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 14, 2017 Category: Pharmaceuticals Source Type: news

Base Erosion and Profit Shifting guidelines stump MNCs
Under BEPS, multinationals will be required to declare details of revenues earned, taxes paid, employees hired, supply chain management in every country they operate in. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 14, 2017 Category: Pharmaceuticals Source Type: news

MSF drags govt to Delhi HC over Pfizer's pneumonia vaccine patent
The Indian patent office granted Pfizer a patent for its vaccine PCV13 (13-valent pneumococcal conjugate vaccine), sold here under the brand ‘Prevenar13’ for over 10 years. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 13, 2017 Category: Pharmaceuticals Source Type: news

Bayer to sell selected crop science biz to BASF for $7 billion
"In light of the planned acquisition of Monsanto, Bayer has signed an agreement to sell selected Crop Science businesses to BASF for EUR 5.9 billion," Bayer said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 13, 2017 Category: Pharmaceuticals Source Type: news

Pfizer reviewing alternatives for consumer healthcare business
Pfizer consumer healthcare develops, manufactures and markets leading non-prescription medicines, vitamins, and personal care products. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 11, 2017 Category: Pharmaceuticals Source Type: news

Lupin's US arm takes over Symbiomix Therapeutics
Lupin had entered into an arrangement to acquire the company earlier this year. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 11, 2017 Category: Pharmaceuticals Source Type: news

Piramal Pharma announces expansion of API manufacturing facilities
PPS will also expand its potency footprint at its plant in Riverview, Michigan, while augmenting early development capabilities out of Ennore in India through additions of GMP kilo labs and a pilot plant. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 10, 2017 Category: Pharmaceuticals Source Type: news

Lupin launches pain relieving generic tablets in US
Lupin's product is a generic version of Allergan Sales LLC's Norco tablets in the same strengths and is indicated for relief of moderate to moderately severe pain. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 10, 2017 Category: Pharmaceuticals Source Type: news

USFDA issues CRL for proposed biosimilar Pegfilgrastim: Biocon
The company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 10, 2017 Category: Pharmaceuticals Source Type: news

Biocon gets CRL from USFDA for anti-cancer drug
The company, however, said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 10, 2017 Category: Pharmaceuticals Source Type: news

Suven Life gets patent from New Zealand for neurological drug
Suven Life said it has been granted "one product patent from New Zealand corresponding to the NCEs for the treatment of disorders associated with neuro-degenerative diseases". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 10, 2017 Category: Pharmaceuticals Source Type: news

Drug-makers may have to declare `ex-factory' price on medicine packs
The proposal has perturbed pharma cos as it will put their manufacturing cost, profits and margins in the public domain. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 10, 2017 Category: Pharmaceuticals Source Type: news

Lupin gets USFDA nod to market hypertension treatment tablets
The product is a generic version of US WorldMeds LLC's Corgard tablets in the same strengths, said Lupin. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 9, 2017 Category: Pharmaceuticals Source Type: news

Marksans Pharma gets EIR from USFDA for its Goa facility
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 9, 2017 Category: Pharmaceuticals Source Type: news

India plans to lessen its drug reliance on China
Currently, India gets 80% of its medicine supplies from China. Following Doval ’s alert, govt had formed a panel to formulate a policy to boost API manufacturing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 8, 2017 Category: Pharmaceuticals Source Type: news

HC asks Centre, Maharashtra to list steps taken to regulate online
The directions came while the bench was hearing a Public Interest Litigation seeking that the government tackle illegal sale of 'Schedule H' or prescription medicines online. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2017 Category: Pharmaceuticals Source Type: news

Zydus Cadila gets USFDA nod to market antidepressant drug
"The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process by the company," it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2017 Category: Pharmaceuticals Source Type: news

Gland Pharma to leverage Fosun ’s strengths for growth
Biologics and biosimilar drugs are emerging hotspots, and Gland is arming itself to take a leap in this segment, which is estimated to be the around $30 billion globally. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 5, 2017 Category: Pharmaceuticals Source Type: news

Novartis divests anti-infectives brands to Samara Capital
The portfolio of brands acquired focus on anti-infectives largely catering to the women's health and gynaecology segment, the spokesperson added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 5, 2017 Category: Pharmaceuticals Source Type: news

Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 billion
Fosun Pharma and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 4, 2017 Category: Pharmaceuticals Source Type: news

After Gland, Chinese pharma giant Fosun eyes API maker Symbiotec
​​Symbiotec has been an acquisition target for other drug makers and PE players after the Indore-based company was put up for sale. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 1, 2017 Category: Pharmaceuticals Source Type: news

Overuse of antibiotics in animals to worsen India ’s AMR problem: Study
​India is expected to see an 82% increase in consumption of antibiotics in “food animals” from 2,633 tons of antibiotics in 2013, showed a new study. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 29, 2017 Category: Pharmaceuticals Source Type: news

Hilleman Laboratories receives Swedish grant for oral cholera vaccine
The World Health Organisation estimates that there are nearly every year there are roughly 1.3 to 4 million cases Cholera cases globally and cause of nearly 21 000 to 143 000 deaths globally. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 28, 2017 Category: Pharmaceuticals Source Type: news

Pharma in pain again, investors dump stocks
Worryingly, experts feel that the pain in the sector may persist for a while and shares may remain under pressure in the coming days. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 28, 2017 Category: Pharmaceuticals Source Type: news

Pharma companies lag in digital journey against global counterparts
EY's Digital maturity Index (EYDI), a five-step digital maturity framework, showed that Indian pharmaceutical companies lag behind in their digital journey when compared to their global counterparts. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 27, 2017 Category: Pharmaceuticals Source Type: news

Speciality segment to be a key growth driver for Sun Pharma
While these investments currently do not generate commensurate revenues streams, they will augur well for the company in the long term as more speciality products get commercialised. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 26, 2017 Category: Pharmaceuticals Source Type: news

Currency fluctuation in semi regulated markets to hit Indian pharma: Fitch
It also noted that most Indian exporters are rationalising presence among semi-regulated markets, avoiding markets where risks outweigh opportunities. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 26, 2017 Category: Pharmaceuticals Source Type: news